Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 성주명 | - |
dc.date.accessioned | 2018-06-02T08:14:22Z | - |
dc.date.available | 2018-06-02T08:14:22Z | - |
dc.date.issued | 2005 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.other | OAK-17578 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/244103 | - |
dc.description.abstract | Background: To compare the mobilizing effects and toxicities of two different doses of cyclophosphamide (CY) plus lenograstim (glycosylated G-CSF), we performed a prospective randomized study by enrolling patients suffering with either high-risk Non-Hodgkin's lymphoma (NHL) or breast cancer undergoing ablative chemotherapy. Methods: The NHL patients received 4 cycles of CHOP and the breast cancer patients received 2-3 cycles of FAC (FEC) adjuvant chemotherapy. Then, the patients were randomly allocated to receive CY 4 g/m2 (arm A) or 1.5 g/m2 (arm B) in combination with lenograstim. Large volume leukapheresis was carried out and it was continued daily until the target cell dose of 2 × 106 CD34+ cell/kg was reached. Results: Twenty-seven patients were enrolled in the study. The median number of leukaphereis sessions actually performed was 2.5 sessions in arm A and 3 sessions in arm B. The target cell dose was obtained with the median number of one leukapheresis session in both arms of the study (p=0.09). The collected number of CD34+ cells in the leukapheresis products was higher in arm A than arm B (22.4 vs. 9.9 × 106/kg, respectively, p=0.05). Grade III or IV leukopenia was present in 14/15 patients (94%) in arm A and in 1/12 patients (8%) in arm B (p<0.0001). Grade III or IV thrombocytopenia was present in 8/15 patients (54%) in arm A, but this was not present in any patients of arm B (p=0.0004). Neutropenic fever occurred in 6/15 patients (40%) in arm A, and in 1/12 patients (8%) in arm B (p=0.09). The hematological recovery of the leukocytes and platelets after transplantation was not statistically different between the two doses. Conclusion: Low-dose CY plus lenograstim is a safe and effective mobilizing regimen. | - |
dc.language | English | - |
dc.title | High-dose versus low-dose cyclophosphamide in combination with G-CSF for peripheral blood progenitor cell mobilization | - |
dc.type | Article | - |
dc.relation.issue | 3 | - |
dc.relation.volume | 20 | - |
dc.relation.index | SCIE | - |
dc.relation.index | SCOPUS | - |
dc.relation.index | KCI | - |
dc.relation.startpage | 224 | - |
dc.relation.lastpage | 231 | - |
dc.relation.journaltitle | Korean Journal of Internal Medicine | - |
dc.identifier.scopusid | 2-s2.0-28444440311 | - |
dc.author.google | Ahn J.S. | - |
dc.author.google | Park S. | - |
dc.author.google | Im S.-A. | - |
dc.author.google | Yoon S.-S. | - |
dc.author.google | Lee J.-S. | - |
dc.author.google | Kim B.K. | - |
dc.author.google | Bang S.-M. | - |
dc.author.google | Cho E.K. | - |
dc.author.google | Lee J.H. | - |
dc.author.google | Jung C.W. | - |
dc.author.google | Kim H.C. | - |
dc.author.google | Seong C.M. | - |
dc.author.google | Lee M.H. | - |
dc.author.google | Kim C.S. | - |
dc.author.google | Lee K.S. | - |
dc.author.google | Lee J.A. | - |
dc.author.google | Ahn M.-J. | - |
dc.contributor.scopusid | 성주명(7005537065) | - |
dc.date.modifydate | 20230210133150 | - |